The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995-2012.
about
Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval.Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.
P2860
The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995-2012.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The impact of pharmaceutical i ...... ity in Switzerland, 1995-2012.
@en
type
label
The impact of pharmaceutical i ...... ity in Switzerland, 1995-2012.
@en
prefLabel
The impact of pharmaceutical i ...... ity in Switzerland, 1995-2012.
@en
P2860
P1476
The impact of pharmaceutical i ...... ity in Switzerland, 1995-2012.
@en
P2093
Frank R Lichtenberg
P2860
P2888
P304
P356
10.1007/S10198-015-0725-6
P577
2015-09-05T00:00:00Z